Dacarbazine

Adrenal Medulla, Metastatic Melanoma, Hodgkin's Lymphoma + 3 more
Treatment
4 FDA approvals
20 Active Studies for Dacarbazine

What is Dacarbazine

DacarbazineThe Generic name of this drug
Treatment SummaryDacarbazine is a medication used to treat melanoma, a type of skin cancer. It is often used in combination with a drug called Oblimersen in clinical trials for the treatment of malignant melanoma.
Dacarbazineis the brand name
image of different drug pills on a surface
Dacarbazine Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Dacarbazine
Dacarbazine
1998
7

Approved as Treatment by the FDA

Dacarbazine, also called Dacarbazine, is approved by the FDA for 4 uses which include Lymphoma, Hodgkins and Metastatic Melanoma .
Lymphoma, Hodgkins
Used to treat Lymphoma, Hodgkins in combination with null
Metastatic Melanoma
Hodgkin's Lymphoma
Used to treat Lymphoma, Hodgkins in combination with null
Metastatic Melanoma

Effectiveness

How Dacarbazine Affects PatientsDacarbazine is a medication that helps to treat certain types of cancer. When taken intravenously, it is distributed throughout the body and is removed from the blood in two phases, with an initial half-life of 19 minutes and a terminal half-life of 5 hours. For patients with kidney or liver issues, the half-life is longer. Approximately 40% of the dose is excreted from the body within 6 hours. Dacarbazine is not strongly bound to proteins in the blood.
How Dacarbazine works in the bodyWe don't know exactly how dacarbazine works, but it seems to kill cells by acting as an alkylating agent. It may also stop cell reproduction by acting as a purine analog, and by interacting with SH groups. Dacarbazine works on cells no matter what stage of the cell cycle they are in.

When to interrupt dosage

The measure of Dacarbazine is contingent upon the recognized condition, comprising of Metastatic Melanoma, advanced Soft Tissue Sarcoma (STS) and Adrenal Medulla. The extent of dosage is outlined in the table below, dependent upon the method of delivery.
Condition
Dosage
Administration
Hodgkin's Lymphoma
, 20.0 mg/mL, 10.0 mg/mL, 200.0 mg, 600.0 mg
Intravenous, Injection, powder, for solution, , Injection, powder, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Pheochromocytoma
, 20.0 mg/mL, 10.0 mg/mL, 200.0 mg, 600.0 mg
Intravenous, Injection, powder, for solution, , Injection, powder, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Adrenal Medulla
, 20.0 mg/mL, 10.0 mg/mL, 200.0 mg, 600.0 mg
Intravenous, Injection, powder, for solution, , Injection, powder, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Sarcoma
, 20.0 mg/mL, 10.0 mg/mL, 200.0 mg, 600.0 mg
Intravenous, Injection, powder, for solution, , Injection, powder, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Pancreatic Hormones
, 20.0 mg/mL, 10.0 mg/mL, 200.0 mg, 600.0 mg
Intravenous, Injection, powder, for solution, , Injection, powder, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Metastatic Melanoma
, 20.0 mg/mL, 10.0 mg/mL, 200.0 mg, 600.0 mg
Intravenous, Injection, powder, for solution, , Injection, powder, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Warnings

There are 20 known major drug interactions with Dacarbazine.
Common Dacarbazine Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Dacarbazine is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Dacarbazine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Dacarbazine is combined with Abetimus.
Acenocoumarol
Major
The metabolism of Acenocoumarol can be decreased when combined with Dacarbazine.
Acteoside
Major
The risk or severity of adverse effects can be increased when Dacarbazine is combined with Acteoside.
Dacarbazine Toxicity & Overdose RiskThe lowest toxic dose of this drug in mice is 350mg/kg when taken orally.
image of a doctor in a lab doing drug, clinical research

Dacarbazine Novel Uses: Which Conditions Have a Clinical Trial Featuring Dacarbazine?

170 active studies are examining the use of Dacarbazine for Metastatic Melanoma, advanced Soft Tissue Sarcoma (STS) and Pheochromocytomas treatment.
Condition
Clinical Trials
Trial Phases
Adrenal Medulla
0 Actively Recruiting
Pheochromocytoma
0 Actively Recruiting
Pancreatic Hormones
0 Actively Recruiting
Metastatic Melanoma
0 Actively Recruiting
Hodgkin's Lymphoma
63 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1
Sarcoma
6 Actively Recruiting
Phase 1, Phase 2

Dacarbazine Reviews: What are patients saying about Dacarbazine?

5Patient Review
10/3/2009
Dacarbazine for A Malignant Pigmented Mole or Tumor
4Patient Review
10/8/2009
Dacarbazine for Disease with Enlarged Lymph Tissue, Spleen and Liver
My wife was treated for stage 3 metastatic melanoma with cisplatin, vinblastin, dtic, IL 2 and interferon at MD Anderson in Houston Tx. She had all the side effects of the D T I C but that is better than death!! Thank G O D FOR THE SUPER INTELIGENT AND CARING PEOPLE AT MD ANDERSON CANCER CENTER
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about dacarbazine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is dacarbazine an immunotherapy or chemo?

"Cancers of the skin is a type of cancer that commonly affects the skin. Dacarbazine is a standard chemotherapy drug that is used to treat this type of cancer. It has a response rate of 10-20% and the median duration of response is 3-6 months."

Answered by AI

What is the drug dacarbazine used for?

"Dacarbazine is a medication used to treat cancer. It belongs to a group of medications called alkylating agents. Alkylating agents work by killing cancer cells. Dacarbazine is used to treat cancer of the lymph system and malignant melanoma (a type of skin cancer). It may also be used to treat other types of cancer, as determined by your doctor."

Answered by AI

What does dacarbazine do for cancer?

"Dacarbazine belongs to a group of chemotherapy drugs called alkylating agents. These drugs work by sticking to the cancer cell's DNA and damaging it. The DNA is the genetic code that controls everything the cell does. If the DNA is damaged, the cancer cell cannot divide and make more cancer cells."

Answered by AI

What are the side effects of dacarbazine?

"The following are symptoms of chemotherapy: nausea, vomiting, loss of appetite, diarrhea, sores in the mouth and throat, hair loss, feeling of burning or tingling on the face, flushing."

Answered by AI

Clinical Trials for Dacarbazine

Image of St. Jude Children's Research Hospital in Memphis, United States.

High Intensity Interval Training for Hodgkin's Lymphoma Survivors

10 - 25
All Sexes
Memphis, TN
This pilot study evaluates the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment. Preliminary efficacy of the HIIT intervention for improved cardiorespiratory fitness, body composition, physical function, autonomic response to exercise, peripheral neuropathy, biological aging markers, and physical activity will also be evaluated. Primary Objective: To determine the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment. Feasibility will be assessed by: * Participation Rate: Number of eligible survivors approached who enroll. * Completion Rate: Number of scheduled HIIT sessions attended and number of enrolled participants who complete post-intervention testing.
Waitlist Available
Has No Placebo
St. Jude Children's Research HospitalAmy Berkman, MD
Image of City of Hope Medical Center in Duarte, United States.

CMV-MVA Triplex Vaccine for Cancer

18 - 75
All Sexes
Duarte, CA
This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cell transplantation (haploHCT) has advanced to become the predominant procedure for patients lacking a matched donor. Compared to matched related donor transplants, the rate of significant CMV infection is higher in patients undergoing a haploHCT. Significant CMV infection is associated with an increased risk of complications and death. Vaccination is the main preventative approach to limit complications and death in immunocompromised patients at high risk of post-stem cell transplant infections. CMV-MVA Triplex vaccine, is a CMV vaccine based on the attenuated poxvirus, modified vaccinia Ankara (MVA), developed to enhance CMV-specific immunity in both healthy stem cell transplant donors and stem cell transplant patients to prevent significant CMV infection post-stem cell transplant. Giving CMV-MVA triplex vaccine may be safe, tolerable and/or effective in enhancing cytomegalovirus (CMV)-specific immunity and preventing CMV viremia in patients undergoing a haploHCT.
Phase 1
Waitlist Available
City of Hope Medical Center (+2 Sites)Ryotaro Nakamura
Have you considered Dacarbazine clinical trials? We made a collection of clinical trials featuring Dacarbazine, we think they might fit your search criteria.Go to Trials
Image of University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center in Cleveland, United States.

Abatacept for Leukemia

18 - 65
All Sexes
Cleveland, OH
The goal of this clinical trial is to see if adding abatacept to tacrolimus and MMF prevents or reduces the chances of acute graft versus host disease which is a complication that can occur after transplant in participants with blood cancer. The usual therapy for graft versus host disease prevention after a cord blood transplant includes tacrolimus and MMF. The main question this clinical trial aims to answer is whether or not abatacept will be safe and effective in reducing aGVHD rates in dCBT. Participants will: * Partake in exams, tests, and procedures as part of usual cancer care. * Partake in conditioning, which is the treatment that is given before a transplant. * Have a cord blood transplant. * Partake in radiation following the transplant.
Phase 2
Recruiting
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer CenterLeland Metheny, MD
Image of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, United States.

Darzalex Faspro for Blood Cancers

18+
All Sexes
Baltimore, MD
This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor specific antibodies (DSA) levels to low enough levels to permit patients to proceed with allogeneic peripheral blood transplant (alloBMT). Those being asked to participate have high DSA levels that puts those being asked to participate at high risk of rejecting the available donor's blood stem cells and making those being asked to participate ineligible to receive a stem cell transplant.
Phase < 1
Recruiting
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsChristian B Gocke, MD, PhDJanssen Research & Development, LLC
Have you considered Dacarbazine clinical trials? We made a collection of clinical trials featuring Dacarbazine, we think they might fit your search criteria.Go to Trials
Image of Houston Methodist Hospital in Houston, United States.

CAR-T Cell Therapy for Lymphoma

12 - 75
All Sexes
Houston, TX
This study involves patients that have a cancer called diffuse large B cell lymphoma (DLBCL), Natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to collectively as lymphoma). Patients' lymphoma has come back or not gone away after treatment. A previous research study at Baylor combined two ways of fighting disease: antibodies and T cells. Antibodies are proteins that bind to bacteria, viruses and other foreign substances to prevent disease. T-cells are special infection-fighting white blood cells that can kill tumor cells or cells infected with bacteria and viruses. Both have shown promise treating cancer, but neither has been strong enough to cure most patients. In the previous study, an antibody called anti-CD30 which is found on the surface of some T-cells and cancer cells, and had been used to treat lymphoma with limited success, was joined to the T-cells through a process called gene transfer, resulting in CD30.CAR T cells. Another study saw encouraging responses using CD30.CAR T cells made in a lab from a patients' own blood then injected back into the same patient to treat their lymphoma. These cells are termed 'autologous' because they're given back to the original patient. In an ongoing study, patients were treated with allogeneic CD30.CAR T cells, which are made from healthy donors instead of the patients. The use of allogenic cells avoids a lengthy manufacture time since the products are stored as a bank and available on demand. This ongoing trial has preliminarily shown promising clinical activity with no safety concerns. With the current study, investigators plan to extend the anti-cancer effects of the CD30.CAR T cell by attaching another molecule called C7R, which has made CAR T cells have deeper and longer anticancer effects in the laboratory. The aim is to study the safety and effectiveness of allogeneic banked CD30.CAR-EBVST cells that also carry the C7R molecule, to learn the side effects of C7R modified CD30.CAR-EBVST cells in lymphoma patients, and to see whether this therapy may help them. As an extra safety step, the C7R containing T cells will also have a marker called iC9. If a patient experiences intolerable side effects from the C7R T cells, they could receive a medication called 'rimiducid' that can eliminate the C7R containing T cells by binding iC9, thereby potentially resolving the side effects. While not yet FDA approved, rimiducid has been tested in patients before without bad side effects.
Phase 1
Recruiting
Houston Methodist Hospital (+1 Sites)Premal Lulla, MD
Image of Lineberger Comprehensive Cancer Center in Chapel Hill, United States.

Cell Therapy for Hodgkin's Lymphoma

18+
All Sexes
Chapel Hill, NC
Despite the progress in the therapy, Hodgkin's Lymphoma (HL) remains fatal for more than 15% of patients. Even in patients who are cured, the morbidity of therapy is substantial and long-lasting. New therapeutic agents are required therefore not only to further reduce mortality but also to alleviate morbidity. The majority of HL express the CD30 antigens. CD30 expression is routinely used for the diagnosis of HL. Preclinical observations support CD30 as a viable target of CAR-T therapy. This phase Ib/II study was conducted based on these observations. The purpose of this study is to determine the tolerability of ATLCAR.CD30.CCR4 cells in subjects with Hodgkin's Lymphoma and identify a recommended dose for further. This is a single-center, open-label phase Ib/II trial that uses a 3+3 design to identify a recommended phase 2 dose (RP2D) of ATLCAR.CD30.CCR4 cells in Hodgkin's Lymphoma. The phase II portion is designed to determine the PFS of ATLCAR.CD30.CCR4 in Hodgkin's Lymphoma. Subjects will be enrolled on 1 of 3 dose levels as determined by a 3+3 design. Up to 25 evaluable subjects may then be enrolled in the phase II portion of the study. Subjects may have cells procured to manufacture the ATLCAR.CD30.CCR4 cells if they meet eligibility for procurement. During the time period necessary to manufacture the ATLCAR.CD30.CCR4 cells, Subjects will be allowed to receive standard-of-care bridging therapy at the discretion of their local oncologist. Prior to cell infusion, subjects will undergo additional eligibility evaluations, and then if eligible, will undergo lymphodepletion followed by cell infusion 2-14 days later. Subjects will then be followed for 15 years as is required for studies involving gene transfer experiments.
Phase 1 & 2
Recruiting
Lineberger Comprehensive Cancer CenterNatalie Grover, MD
Have you considered Dacarbazine clinical trials? We made a collection of clinical trials featuring Dacarbazine, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security